Literature DB >> 1752943

An idiotypic marker associated with a germ-line encoded kappa light chain variable region that predominates the vaccine-induced human antibody response to the Haemophilus influenzae b polysaccharide.

A H Lucas1, R J Langley, D M Granoff, M H Nahm, M Y Kitamura, M G Scott.   

Abstract

Human antibodies specific for the Haemophilus influenzae b polysaccharide (Hib PS) frequently express a cross-reactive idiotype (CRI), and commonly utilize a VL region that is the product of the V kappa II gene A2. To examine further anti-Hib PS V region expression and to determine whether CRI expression is correlated with the V kappa IIA2 chain, we isolated a monoclonal antibody (MAb) reactive with an idiotypic determinant of anti-Hib PS antibodies. This MAb inhibited Hib PS binding but did not react with Ig isotypic determinants. The CRI recognized by this MAb, designated HibId-1, was associated with the Hib PS-combining site since the reactivity of the MAb with anti-Hib PS antibodies could be inhibited by Hib PS. HibId-1 was expressed by 17 of 17 clonally purified and sequence-defined anti-Hib PS antibodies having V kappa IIA2 L chains. In contrast, 0 of 10 anti-Hib PS antibodies having either V lambda, V kappa I, or V kappa III chains expressed HibId-1. Western blot analysis showed that the MAb anti-CRI reacted with isolated anti-Hib PS V kappa IIA2 L chains but not with H chains or other L chains, indicating that the HibId-1 determinant is localized to the V kappa IIA2 chain, and does not require pairing with H chain for expression. Anti-Hib PS antibodies bearing HibId-1 were present in at least 85% of subjects immunized with either free Hib PS or Hib PS coupled to diphtheria toxoid (Hib PS-DT), and comprised on the average 60% of the total vaccine-induced serum anti-Hib PS. HibId-1 expression was not related to age at vaccination inasmuch as infants, children, and adults had similar distributions of HibId-1-positive anti-Hib PS after vaccination with Hib PS-DT. HibId-1 was expressed at a lower frequency and comprised a smaller fraction of the total anti-Hib PS antibody in adult preimmunization sera as compared to post-Hib PS immunization sera, suggesting that immunization preferentially stimulates HibId-1-positive B cells. These data demonstrate that antibodies bearing HibId-1/V kappa IIA2 comprise a predominant component of the anti-Hib PS response induced by immunization, and that this pattern of VL expression is established early in ontogeny.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752943      PMCID: PMC295748          DOI: 10.1172/JCI115502

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b.

Authors:  D H Smith; G Peter; D L Ingram; A L Harding; P Anderson
Journal:  Pediatrics       Date:  1973-11       Impact factor: 7.124

3.  Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies.

Authors:  J B Robbins; J C Parke; R Schneerson; J K Whisnant
Journal:  Pediatr Res       Date:  1973-03       Impact factor: 3.756

Review 4.  The generation of diversity in phosphorylcholine-binding antibodies.

Authors:  R M Perlmutter; S T Crews; R Douglas; G Sorensen; N Johnson; N Nivera; P J Gearhart; L Hood
Journal:  Adv Immunol       Date:  1984       Impact factor: 3.543

5.  Complete amino acid sequence of light chain variable regions derived from five monoclonal anti-p-azophenylarsonate antibodies differing with respect to a crossreactive idiotype.

Authors:  M Siegelman; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

6.  Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide.

Authors:  E E Adderson; P G Shackelford; A Quinn; W L Carroll
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

7.  Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B.

Authors:  R A Insel; P W Anderson
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

8.  Normal human B cells display ordered light chain gene rearrangements and deletions.

Authors:  S J Korsmeyer; P A Hieter; S O Sharrow; C K Goldman; P Leder; T A Waldmann
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

9.  Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae.

Authors:  D E Briles; C Forman; S Hudak; J L Claflin
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  28 in total

1.  Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F.

Authors:  A H Lucas; K D Moulton; V R Tang; D C Reason
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 2.  Factors that influence formation of B cell repertoire.

Authors:  A J Feeney
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

3.  Structural requirements of the major protective antibody to Haemophilus influenzae type b.

Authors:  L Hougs; L Juul; A Svejgaard; T Barington
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F.

Authors:  Jianhui Zhou; Kathleen R Lottenbach; Stephen J Barenkamp; Alexander H Lucas; Donald C Reason
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

5.  Polysaccharide binding potential of the human A2 or A18 kappa light chain homologues.

Authors:  D C Reason; T C Wagner; V R Tang; K D Moulton; A H Lucas
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

6.  Aging and the immune response to the Haemophilus influenzae type b capsular polysaccharide: retention of the dominant idiotype and antibody function in the elderly.

Authors:  A H Lucas; D C Reason
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

7.  Comparison of nonhuman primate antibodies against Haemophilus influenzae type b polysaccharide with human antibodies in oligoclonality and in vivo protective potency.

Authors:  K H Kim; M K Park; C C Peeters; J T Poolman; M H Shearer; R C Kennedy; M H Nahm
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

8.  The V-region repertoire of Haemophilus influenzae type b polysaccharide antibodies induced by immunization of infants.

Authors:  G H Chung; K H Kim; R S Daum; R A Insel; G R Siber; S Sood; R K Gupta; C Marchant; M H Nahm
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

9.  Immunoglobulin light chain variable region gene sequences for human antibodies to Haemophilus influenzae type b capsular polysaccharide are dominated by a limited number of V kappa and V lambda segments and VJ combinations.

Authors:  E E Adderson; P G Shackelford; R A Insel; A Quinn; P M Wilson; W L Carroll
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

10.  Variable region sequences and idiotypic expression of a protective human immunoglobulin M antibody to capsular polysaccharides of Neisseria meningitidis group B and Escherichia coli K1.

Authors:  F H Azmi; A H Lucas; H V Raff; D M Granoff
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.